Rituximab: all 1,389 studies that test it
Page 5 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.
- Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01082939Phase 2Results posted
- Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's MacroglobulinemiaTerminatedNCT01078974Phase 1Results posted
- Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)CompletedNCT01073163Phase 3Results posted
- Bortezomib Plus Rituximab for EBV+ PTLDCompletedNCT01058239Phase 2Results posted
- Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's LymphomaCompletedNCT01055496Phase 1Results posted
- Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic CancerTerminatedNCT01044745Phase 2Results posted
- Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin LymphomaCompletedNCT01035463Phase 1/2Results posted
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasCompletedNCT01030900Phase 2Results posted
- Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade LymphomaCompletedNCT01029730Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
- Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic LeukemiaTerminatedNCT01013961Phase 2Results posted
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) LymphomaCompletedNCT01011920Phase 2Results posted
- Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's LymphomaCompletedNCT00994643Phase 2Results posted
- Desensitization of Highly Sensitized Deceased Donor Renal Transplantation CandidatesTerminatedNCT00986947Phase 2Results posted
- Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaCompletedNCT00980395Phase 2Results posted
- Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLLCompletedNCT00974233Phase 2Results posted
- Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaActive, not recruitingNCT00972478Phase 1/2Results posted
- Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
- A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT00949988Phase 1/2Results posted
- Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and RituximabTerminatedNCT00946023Phase 2Results posted
- Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of TestisCompletedNCT00945724Phase 2Results posted
- Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic LeukemiaCompletedNCT00940342Phase 2Results posted
- Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell LeukemiaActive, not recruitingNCT00923013Phase 2Results posted
- Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00918723Phase 1/2Results posted
- Desensitization in Kidney TransplantationCompletedNCT00908583Phase 4Results posted
- Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular LymphomaCompletedNCT00904722Phase 2Results posted
- Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular LymphomaTerminatedNCT00901927Phase 2Results posted
- High Dose Rituximab for Initial Treatment of Indolent B-Cell LymphomasCompletedNCT00895661Phase 2Results posted
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaCompletedNCT00891839Phase 2Results posted
- Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT00878254Phase 2Results posted
- Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT00869999Phase 2Results posted
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisordersTerminatedNCT00869323Phase 2Results posted
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaCompletedNCT00867529Phase 2Results posted
- Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's LymphomaCompletedNCT00867087Phase 2Results posted
- Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT00860457Phase 2Results posted
- A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLLCompletedNCT00858117Phase 2Results posted
- Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular LymphomaCompletedNCT00856245Phase 2Results posted
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentTerminatedNCT00851552Phase 2Results posted
- A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to MethotrexateTerminatedNCT00845832Phase 2Results posted
- Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab TherapyCompletedNCT00844714Not applicableResults posted
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00844298Phase 2Results posted
- Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
- Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant RejectionCompletedNCT00801632Phase 2Results posted
- Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)TerminatedNCT00799773Phase 3Results posted
- Fludarabine, Cyclophosphamide, and Rituximab - High Dose FrontlineCompletedNCT00794820Phase 2Results posted
- Hematopoietic Stem Cell Transplant in Devic's DiseaseCompletedNCT00787722Phase 1/2Results posted
- Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaCompletedNCT00784927Phase 2Results posted
- Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasCompletedNCT00783367Phase 2Results posted
- Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITPCompletedNCT00774202Phase 2/3Results posted
- Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLTerminatedNCT00772668Not applicableResults posted
- Randomized Trial for Mixed Acute RejectionCompletedNCT00771875Phase 2Results posted
- Alemtuzumab + Rituximab Consolidation in CLLTerminatedNCT00771602Phase 2Results posted
- A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)CompletedNCT00770562Phase 3Results posted
- S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT00770224Phase 2Results posted
- Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin LymphomaCompletedNCT00765245Phase 2Results posted
- Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's LymphomaCompletedNCT00764517Phase 2Results posted
- Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00759798Phase 2Results posted
- Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaCompletedNCT00759603Phase 2Results posted
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHLCompletedNCT00732498Phase 2Results posted
- Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And RituximabCompletedNCT00724971Phase 1Results posted
- Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin LymphomaCompletedNCT00720876Phase 2Results posted
- A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)CompletedNCT00719472Phase 3Results posted
- A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00718549Phase 3Results posted
- Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell LymphomaCompletedNCT00712582Phase 2Results posted
- Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaCompletedNCT00711828Phase 2Results posted
- Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
- Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00695409Phase 2Results posted
- The Effect of Rituximab on the Development of Anti-Donor AntibodiesCompletedNCT00695097Not applicableResults posted
- Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin LymphomaTerminatedNCT00691652Phase 1/2Results posted
- Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell LymphomaCompletedNCT00690560Phase 2Results posted
- Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaCompletedNCT00670358Phase 1/2Results posted
- Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/LymphomaCompletedNCT00669877Phase 2Results posted
- Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00669318Phase 2Results posted
- Ph2 Gem/Nov/Rituxan Rel/Ref MantleCellCompletedNCT00656084Phase 2Results posted
- Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin LymphomaCompletedNCT00654732Phase 2Results posted
- Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTCompletedNCT00648037Not applicableResults posted
- A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaCompletedNCT00636792Phase 2Results posted
- A Phase I/II Trial of VR-CHOP in Lymphoma PatientsCompletedNCT00634179Phase 1/2Results posted
- Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
- Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT00625729Phase 1/2Results posted
- Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell TransplantTerminatedNCT00617929Phase 2Results posted
- Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After RituximabCompletedNCT00609869Phase 2Results posted
- Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00602836Phase 2Results posted
- Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
- Trial of Rituximab for Graves' OphthalmopathyCompletedNCT00595335Phase 2/3Results posted
- Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System LymphomaCompletedNCT00594815Not applicableResults posted
- Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined SignificanceTerminatedNCT00588822Phase 2Results posted
- Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHLCompletedNCT00588094Phase 2Results posted
- Clinical Trial Evaluating Rituximab in Ocular Cicatricial PemphigoidCompletedNCT00584935Phase 1/2Results posted
- Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell LymphomaCompletedNCT00581776Phase 2Results posted
- Rituximab in Rheumatoid Arthritis Lung DiseaseCompletedNCT00578565Phase 3Results posted
- A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to MethotrexateCompletedNCT00578305Phase 3Results posted
- Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins LymphomaCompletedNCT00577629Phase 2Results posted
- Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaTerminatedNCT00567229Phase 2Results posted
- Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological MalignanciesCompletedNCT00566696Phase 2Results posted
- Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic LeukemiaCompletedNCT00562328Phase 2Results posted
- Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaCompletedNCT00553501Phase 2Results posted
- Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaCompletedNCT00547534Phase 2Results posted
- Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell CancerCompletedNCT00546377Phase 1/2Results posted
- A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)CompletedNCT00545714Phase 2Results posted